Image: Magnyfying glass © Creatas, SuperStock

One-half of a strange year is in the books, and for all the economic drama, returns on most U.S.-stock mutual funds were tightly bunched around the mid-single digits -- with one happy exception.

While I think it's useful to understand what happened at the largest actively managed stock funds in the year's first half, you don't want to lose perspective. The surest way to wreck a portfolio is to make decisions based on short-term performance.

You judge a manager by his or her entire record, not by one six-month stretch. All evidence suggests that the long term is what matters. Please read the analyses to get Morningstar's take on whether each fund is a worthy investment.

Health care, real estate and utilities were the best sectors in the first half of 2011, while financials, natural resources and technology were duds. In terms of fund style, small growth and mid growth fared best, while small value and large growth were laggards.

Overall, the first half wasn't all that glorious for the following 10 giants, listed largest to smallest. Three were in the top quartile, but one was in the bottom quartile and two were just barely above it.

1. American Funds Growth Fund of America (AGTHX)-- 4.6% return, rank 69 (1=best and 100=worst)

A sizable overweighting of financials such as Citigroup (C, news) and Wells Fargo (WFC, news) led to a sluggish first half for the biggest actively managed stock fund. It didn't help that it had Google (GOOG, news) and Microsoft (MSFT, news) among other top holdings. (Microsoft owns and publishes MSN Money.)

The fund has nine managers, plus it hands a stake to the firm's analysts. So, for a stock to make it into the top holdings, at least a couple of managers would have to be on board.

As a side note, many shareholders are voting with their feet; this fund's $9.5 billion in year-to-date outflows is the largest of any fund.

2. Fidelity Contrafund (FCNTX)-- 4.4% return, rank 72

Manager William Danoff has a third of the portfolio in tech, but he's been light on health care. So, it wasn't an ideal sector stance for the year's first half.

But the most interesting part of the tech story is that Danoff bought stakes in Facebook and Groupon ahead of their initial public offerings. Given the limited supply of shares, both stakes represent small slivers of the fund. Still, Danoff isn't one to pass up a stock that can boost performance, even if just by a small amount.

Danoff doesn't write off smaller and less-liquid positions just because they can't be a big part of this $80 billion fund on their own. In the past he's bought baskets of small- or mid-cap names in a particular industry he wants exposure to.

3. American Funds Investment Company of America (AIVSX)-- 3.9% return, rank 83

Management was right to underweight financials, but a technology overweighting and a health care underweighting have held the fund back. Like their brethren at American Funds Growth Fund of America, the seven managers here have been stung by Microsoft and Google, and they also have shares of laggard Hewlett-Packard (HPQ, news).

4. American Funds Fundamental Investors A (ANCFX)-- 6.1% return, 32 rank

All right! Our first outperformer. The fund was nicely underweight financials and technology. Also on the plus side, management has done well with tobacco supplier Philip Morris International (PM, news), medical products developer Basic Energy Services (BAS, news) and drug-maker Bristol-Myers Squibb (BMY, news) -- now that's playing both sides of the street.

The fund also had the modest benefit of having the biggest foreign-stock weighting of our top 10 -- 22% of assets. Nearly all of that was in Europe. Despite the Hellenic tragedy, European stocks performed a little better than U.S. stocks in the first half of 2011.

5. American Funds Washington Mutual A (AWSHX)-- 8.1% return, 14 rank

This is America's most dividend-oriented fund, and that's made it a good spot to be in this year. Stakes in such oil majors as Chevron (CVX, news) and Royal Dutch Shell (RDS.A, news) led to solid results, as did exposure to some big telecom companies.

6. Dodge & Cox Stock (DODGX)-- 6.3% return, 34 rank

Being overweight in health care and technology has been a mixed bag. Drug-makers Pfizer (PFE, news) and Sanofi-Aventis (SNY, news) helped, but tech titan Hewlett-Packard hurt.

All three are good representatives of Dodge's value style. The fund favors companies with strong positions but shares that are cheap because they seem to be at a low, cyclical ebb.

Dodge bets on a comeback and figures the low valuations will provide some downside protection if the bet is wrong.

7. Fidelity Growth Company (FDGRX)-- 10.2% return, 3 rank

Steven Wymer's fund is the star performer of our group of 10, with a double-digit gain for the first six months of the year. Wymer got there by taking on more risk than any other fund on the list, and it paid off.

The closed fund sports names, such as apparel maker Lululemon Athletica (LULU, news), software supplier Salesforce.com (CRM, news), Linux distributor Red Hat (RHT, news) and drug-maker Alexion Pharmaceuticals (ALXN, news), that you won't see in the other portfolios.

Not surprisingly, the fund also led this group of giants in the snapback year of 2009. Wymer buys smaller, faster-growing companies than you'll find in the other funds here.

8. Vanguard Windsor II (VWNFX)-- 6.9% return, 26 rank

Lead manager Jim Barrow plays an extreme version of the Dodge & Cox strategy. He likes stuff that's really cheap and really battered. Yet interestingly, he's got some of the same names you'll find in the Dodge & Cox fund, such as Pfizer. You know Pfizer has fallen a long way when the former growth darling makes it into Barrow's portfolio.

9. Fidelity Low-Priced Stock (FLPSX)-- 8.6% return, 22 rank

Joel Tillinghast was in the middle of the mid-blend pack at the end of May, but then the market hit an air pocket. He finished the first half in the top quartile, because his defensive strategy tends to lose less in down markets.

Click here to become a fan of MSN Money on Facebook

As usual, it's an eclectic group of names that pushed this 800-stock portfolio to outperformance. Names such as insurer UnitedHealth Group (UNH, news) and fashion accessories provider Fossil (FOSL, news) led the charge.

10. Vanguard Primecap (VPMCX)-- 5.5% return, 54 rank

The growth stalwarts at this closed fund are having a middling year despite a big health care bet. While Biogen Idec (BIIB, news) has been a big winner, names such as Amgen (AMGN, news) and Roche (RHHBY, news) have been dull. Moreover, this is another fund that sustained that one-two punch from Google and Microsoft.